Flatiron Health has secured a partnership with Japan’s National Cancer Center Hospital East (NCCHE) to develop a database of patients with gastrointestinal cancers.
According to the signed agreement, data from consenting NCCHE patients will be created into datasets to assist NCCHE with making treatment decisions and support its research-oriented activities, a Jan. 26 press release stated.
“Insights from Flatiron’s U.S.-derived real-world data have brought important treatment alternatives to patients with cancer around the world,” said Carolyn Starrett, Flatiron CEO. “Adding more patient experiences into the evidence that supports treatment, development and regulatory decisions is the best hope for truly transforming global cancer research and care. This agreement marks a major milestone in our commitment to bring Flatiron’s real-world data expertise into partnerships with hospitals and health networks in Asia and Europe.”
The datasets will be accessible to SCRUM-Japan, an industry-academia collaborative whose members include NCCHE, the release stated.
“We are honored to partner with NCCHE, one of Japan’s most influential cancer centers, and to collaborate with SCRUM-Japan, one of the most important cancer genomic screening national projects in the world,” said Hiroshi Kojima, head of market development, Flatiron Health K.K., in the release.
Flatiron International subsidiaries in Japan, Germany, and the United Kingdom will also partner with hospitals and health networks to compile data for further production, according to the release.
“Each Flatiron International partnership is tailored to local, legal, regulatory, data privacy and compliance standards and requirements, and designed to help local healthcare providers and partners generate and utilize high-quality RWD to advance oncology research and care,” said Nathan Hubbard, vice president, head of business development and Flatiron International, in the release.
Flatiron was founded in 2012 and has acquired some of the most creative and boldest minds across the globe to create a transformational change in how cancer is perceived and treated, the release stated.